Obesity-approved GIP and GLP-1 agonist medicine spending growth
Annual growth in medicine spending contributed by GIP and GLP-1 receptor agonists approved for obesity and related comorbidities.
Unit billion USD Industry Pharmaceuticals
The chart
The figure
One published observation so far. A chart follows as soon as a second period is published.
Obesity-approved GIP and GLP-1 agonist medicine spending growth
United States, 2025
Every record
All records
1 record · 1 region · 2025
Primary documents
Sources
1 document. Each links to the publisher's own copy.
| Document | Publisher | Published | Data points |
|---|---|---|---|
| U.S. Medicine Use Trends 2026 | IQVIA | — | 1 |
Cite & reuse
Cite this page
Data on this page is published under CC BY 4.0. You may reuse it, including commercially, provided you attribute it. To cite one figure, open its record: each carries APA, MLA, Chicago and BibTeX forms that credit the original publisher.
StatOrigin. (2026). Obesity-approved GIP and GLP-1 agonist medicine spending growth. Retrieved from https://statorigin.org/indicators/obesity-approved-gip-and-glp-1-agonist-medicine-spending-growth